COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

First-in-Human Single Ascending and Multiple Dose of GLPG0555

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01023321
Recruitment Status : Completed
First Posted : December 2, 2009
Last Update Posted : August 12, 2010
Information provided by:
Galapagos NV

Brief Summary:

The purpose of the study is to evaluate the safety and tolerability of single ascending (SAD) and multiple (MD) oral dose of GLPG0555 compared to placebo.

Also, pharmacokinetics (PK) and pharmacodynamics (PD) of GLPG555 after single and multiple oral administration will be evaluated, and, if applicable, the maximum tolerated dose determined.

Condition or disease Intervention/treatment Phase
Healthy Drug: GLPG0555 Drug: placebo Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 35 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Official Title: Double Blind Placebo Controlled Dose Ranging Study for the Assessment of Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single Ascending and Multiple Oral Doses of GLPG0555 in Healthy Subjects.
Study Start Date : December 2009
Actual Primary Completion Date : April 2010
Actual Study Completion Date : May 2010

Arm Intervention/treatment
Experimental: 1
single ascending doses
Drug: GLPG0555
single ascending doses, oral solution

Placebo Comparator: 2
single dose placebo
Drug: placebo
single dose, oral solution

Experimental: 3
multiple dose, 7 or 14 days, oral solution
Drug: GLPG0555
multiple dose, oral solution, 7 or 14 days

Placebo Comparator: 4
multiple dose, 7 or 14 days, oral solution
Drug: placebo
multiple dose, oral solution, 7 or 14 days

Primary Outcome Measures :
  1. Safety and tolerability of single and multiple dosing [ Time Frame: up to 10 days postdose ]

Secondary Outcome Measures :
  1. Pharmacokinetics of single and repeated doses, including effect of food. [ Time Frame: up to 10 days postdose ]
  2. To characterize the in/ex vivo pharmacodynamics (PD) of GLPG0555 after single and repeated oral administration [ Time Frame: up to 72 hours postdose ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • healthy male, age 18-50 years
  • BMI between 18-30 kg/m², inclusive.

Exclusion Criteria:

  • significantly abnormal platelet function or coagulopathy
  • smoking
  • drug or alcohol abuse

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01023321

Layout table for location information
SGS Stuivenberg
Antwerp, Belgium
Sponsors and Collaborators
Galapagos NV
Layout table for investigator information
Study Director: Gerben van 't Klooster, PhD Galapagos NV
Principal Investigator: Wouter Haazen, MD SGS Stuivenberg

Layout table for additonal information
Responsible Party: Senior Vice President Development, Galapagos NV Identifier: NCT01023321    
Other Study ID Numbers: GLPG0555-CL-101
First Posted: December 2, 2009    Key Record Dates
Last Update Posted: August 12, 2010
Last Verified: August 2010
Keywords provided by Galapagos NV: